NDC-002

NDC-002 is an investigational combination drug developed by DR.Noah Biotech for the treatment of stroke and dementia. It is being developed as a combinatory therapy consisting of two agents, based on the company's proprietary ARK platform, which leverages AI-driven drug discovery. The drug is administered orally and has reached Phase 1 clinical trials for dementia. DR.Noah Biotech focuses on rare and neurological diseases, with NDC-002 representing one of its lead pipeline candidates targeting nervous system disorders. Preclinical research also suggests that naproxen-derived compounds (NDCs) like NDC-2 may have chemotherapeutic effects in cancer models via cyclooxygenase 2 (COX-2) inhibition, but the primary clinical focus for NDC-002 remains stroke recovery and dementia.

Other names

donepezil + acetylcysteinedonepezil + N-acetylcysteineNDC-002ANDC002ANDC 002ANDC-002BNDC002BNDC 002BNDC-002CNDC002CNDC 002C